Orphazyme develops therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases. The Company focuses on development of cell-protective properties of the heat shock response, a natural defense mechanism in various cells; and arimoclomol, an investigative medicinal product that regulates the production of other proteins in the cell.
Net income (H1, 2020)
EBIT (H1, 2020)
Market capitalization (19-Oct-2020)
Closing stock price (19-Oct-2020)
|Company Name||Date||Deal Size|
|Orphazyme Schweiz GmbH|
|Orphazyme US, Inc|
Orphazyme has 680 Twitter Followers. The number of followers has increased 4.1% month over month and increased 7.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Orphazyme founded?
Orphazyme was founded in 2009.
Who are Orphazyme key executives?
Orphazyme's key executives are Kim Stratton, Anders Vadsholt and Thomas Blaettler.
How many employees does Orphazyme have?
Orphazyme has 114 employees.
Who are Orphazyme competitors?
Competitors of Orphazyme include Rocket Pharmaceuticals, ARCA biopharma and Ultragenyx Pharmaceutical.
Where is Orphazyme headquarters?
Orphazyme headquarters is located at Ole Maaløes Vej 3, København.
Where are Orphazyme offices?
Orphazyme has offices in København, Chicago and Newton.
How many offices does Orphazyme have?
Orphazyme has 3 offices.
Receive alerts for 300+ data fields across thousands of companies